Clinical Trial

Evaluation of the Efficacy of Pulmonary Vein Isolation by Pulsed-field Ablation in Persistent Atrial Fibrillation: a Multicenter Study With Follow-up by Implantable Cardiac Monitor

Study acronym: PersAF ICM
Recruiting
View on ClinicalTrials.gov →
Summary
Atrial fibrillation (AF) is the most common sustained arrhythmia in adult population. According to current guidelines for the management of AF, radiofrequency (RF) ablation (including at least pulmonary vein isolation \[PVI\]) is a validated therapeutic option for persistent AF. Recently, Pulsed-field ablation (PFA) - a new non-thermal energy - has been used to treat paroxysmal and persistent AF with a high success rate in observational studies. This new technology is based on tissue-specificity on myocardium, avoiding collateral damages on adjacent structures. Before confirming a superiority of PFA over existing thermal energies, prospective studies concerning an exclusive population of persistent AF patients are needed, with rigorous assessment of the recurrences using continuous monitoring (insertable cardiac monitor \[ICM\]). PFA efficacy using ICM has never been evaluated. Before considering PFA in therapeutic strategies through large-scale randomized studies using rigorous monitoring of recurrences, preliminary studies are needed in a persistent AF population-only. This pilot cohort study will provide solid data of PFA efficacy (using continuous monitoring of recurrences) for future randomized studies.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-05-21; most recent amendment 2026-06-10.
Status change: Not Yet Recruiting → Recruiting 2026-06-10
Trial Details
NCT Number NCT06985901
Lead Sponsor Centre Hospitalier Universitaire de Nice
Conditions Persistent Atrial Fibrillation
Enrollment 60 participants
Start Date 2026-04-13
Primary Completion 2028-04-13 (estimated)
Study Completion 2030-04-13 (estimated)
Updated on ClinicalTrials.gov 2026-06-11